|
Allele Symbol Allele Name Allele ID |
Tg(Cyp1a1-cre/ERT)1Dwi transgene insertion 1, Douglas J Winton MGI:3829429 |
||||||||||||||||||||||||||||||||||||
| Summary |
8 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• cystic vesicles appear 1 week after treatment with tamoxifen and BNF, earlier than in mutant mice wild-type for Cdx1
|
|
• cystic vesicles appear 1 week after treatment with tamoxifen and BNF, earlier than in mutant mice wild-type for Cdx1
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• tamoxifen- and beta-naphthoflavone-induced mice median survival is 99 days compared to 405 days for wild-type Pten homozygotes or 409 days for wild-type Apc homozygotes
|
|
• 95% of tamoxifen- and beta-naphthoflavone-induced mice exhibit large, flattened, ulcerated lesions in the small intestine unlike control mice homozygous for either a wild-type Pten or Apc allele
|
|
• tamoxifen- and beta-naphthoflavone-induced mice develop invasive adenocarcinomas in the small intestines with luminal ulceration, and both acute and chronic inflammation compared to control mice that exhibit begnin neoplasms
• invasion and destruction of the small intestinal wall and peritoneal serosa results in localized peritonitis in tamoxifen- and beta-naphthoflavone-induced mice
|
|
• invasion and destruction of the small intestinal wall and peritoneal serosa by adenocarcinomas results in localized peritonitis in tamoxifen- and beta-naphthoflavone-induced mice
|
|
• tamoxifen- and beta-naphthoflavone-induced mice develop invasive adenocarcinomas in the small intestines with luminal ulceration, and both acute and chronic inflammation compared to control mice that exhibit begnin neoplasms
• invasion and destruction of the small intestinal wall and peritoneal serosa results in localized peritonitis in tamoxifen- and beta-naphthoflavone-induced mice
|
|
• invasion and destruction of the small intestinal wall and peritoneal serosa by adenocarcinomas results in localized peritonitis in tamoxifen- and beta-naphthoflavone-induced mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice injected with beta-napthoflavone and tamoxifen develop gastric polyps 270 days after induction
|
| N |
• mice injected with beta-napthoflavone and tamoxifen do not show any abnormal bladder morphology and do not develop bladder tumors
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
Urothelial hyperplasia and increased apoptosis in bladder epithelium of Ptentm2Mak/Ptentm2Mak Stk11tm1Keis/Stk11tm1Keis Tg(Cyp1a1-cre/ERT)1Dwi/0 mice
|
• mice injected with beta-napthoflavone and tamoxifen exhibit decreased survival after day 100 of induction, mostly due to bladder blockage
|
|
• mice injected with beta-napthoflavone and tamoxifen develop large papillary bladder tumors by day 125 of induction
• tumor tissue shows signs of spindle-shaped cells, squamous metaplasia, focal microvesicular change, and increase in nuclear-cytoplasmic ratio
|
|
• mice injected with beta-napthoflavone and tamoxifen exhibit enlarged bladders by 125 days of induction
• treatment with rapamycin reduces bladder size
|
|
• mice injected with beta-napthoflavone and tamoxifen develop large papillary bladder tumors by day 125 of induction
• tumor tissue shows signs of spindle-shaped cells, squamous metaplasia, focal microvesicular change, and increase in nuclear-cytoplasmic ratio
|
|
• by day 100 of induction with beta-napthoflavone and tamoxifen, mucosa of bladders is thickened
|
|
• mice injected with beta-napthoflavone and tamoxifen exhibit urothelial hyperplasia by day 50 and 100 of induction
• bladder epithelium of beta-napthoflavone and tamoxifen treated mice shows presence of apoptosis and vacuoles at day 50 of induction
• elevation in proliferation in the urothelium of mice injected with beta-napthoflavone and tamoxifen
• marker analysis indicates that bladder urothelial cells of beta-napthoflavone and tamoxifen injected mice exhibit characteristics of epithelial-mesenchymal transition, with loss of epithelial markers and increases in mesenchymal markers
• treatment with rapamycin reduces urothelial epithelium thickness and suppresses the epithelial-to-mesenchymal transition
|
|
• mice injected with beta-napthoflavone and tamoxifen show bladder obstruction due to tumors
|
|
• mice injected with beta-napthoflavone and tamoxifen exhibit enlarged bladders by 125 days of induction
• treatment with rapamycin reduces bladder size
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| urinary bladder cancer | DOID:11054 |
OMIM:109800 |
J:169565 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• mice injected with beta-napthoflavone and tamoxifen do not show any abnormal bladder morphology and do not develop bladder tumors
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 4 weeks after treatment with tamoxifen and BNF a bias towards the production of secretory cells is detected with an excess of mucous-secreting cells in the upper part of the crypts and towards the bases of the villi
|
|
• 4 weeks after treatment with tamoxifen and BNF crypts become sealed off into cystic vesicles and display a severe degree of hypoproliferation
• by 6 weeks after treatment cystic vesicles persist and are often filled with mucous and detritus
• cystic vesicles continue to persist 19-62 weeks after treatment although the surface epithelium consists of unrecombined cells
|
|
• abnormal and frequently moribund 4 weeks after treatment with tamoxifen and BNF
• an excess of Paneth cells are found by 19-62 weeks after treatment and these cells contain an abnormally abundant number of normal looking secretory granules
|
|
• in some mice polyps containing large irregular vesicles develop after treatment with tamoxifen and BNF
|
|
• by 6 weeks after treatment in isolated areas of the distal ileum recombined crypts have replaced the villi
• beyond 19 weeks these recombined regions develop into antral-like branched tubular glands secreting PASpositive, Alcian Blue-negative mucous
|
|
• 4 weeks after treatment with tamoxifen and BNF villi are misshapen
|
|
• 4 weeks after treatment with tamoxifen and beta-naphthoflavone (BNF) the gut becomes abnormally viscid
• by 6 weeks after treatment dying Paneth cells are commonly seen
|
|
• by 6 weeks after treatment dying Paneth cells are commonly seen
|
|
• recombined cells fail to migrate out of the crypts and up the villi in the intestine
|
|
• 4 weeks after treatment with tamoxifen and BNF crypts become sealed off into cystic vesicles and display a severe degree of hypoproliferation
• by 6 weeks after treatment cystic vesicles persist and are often filled with mucous and detritus
• cystic vesicles continue to persist 19-62 weeks after treatment although the surface epithelium consists of unrecombined cells
|
|
• abnormal and frequently moribund 4 weeks after treatment with tamoxifen and BNF
• an excess of Paneth cells are found by 19-62 weeks after treatment and these cells contain an abnormally abundant number of normal looking secretory granules
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice develop hyperplastic lesions in the bladder unlike wild-type mice that are larger than in Apctm1Tno/Apctm1Tno Tg(Cyp1a1-cre/ERT)1Dwi mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice develop hyperplastic lesions in the bladder unlike wild-type mice
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/16/2024 MGI 6.23 |
|
|
|
||
Analysis Tools